ABSTRACT
Historically, chronic inflammatory demyelinating polyradiculoneuropathies (CIDPs) have constituted the major group of well-documented patients with symmetrical acquired demyelinating polyneuropathy. Diagnostic criteria for CIDP are both clinical, with a pattern of disease tending to affect distal and proximal limbs, and electrophysiological, with defined criteria specifying for a primary demyelinating polyneuropathy.1 These patients respond well to corticosteroids or immunosuppressive agents, and it is understood that they should have no other concomitant disorder, though patients with serum paraproteins have also been included.2
